New drug enters first human tests for autoimmune diseases
NCT ID NCT07276958
Summary
This is the first study in humans to test the safety and side effects of a new drug called LY4298445. It will involve both healthy volunteers and people with systemic lupus erythematosus or rheumatoid arthritis. The main goal is to see how the body handles the drug and to find a safe dose range for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network
RECRUITINGBrisbane, 4006, Australia
Contact Phone: •••-•••-••••
Contact
-
Nucleus Network
NOT_YET_RECRUITINGMelbourne, VIC 3004, Australia
Contact Phone: •••-•••-••••
Contact
-
Peking University First Hospital
NOT_YET_RECRUITINGBeijing, 100034, China
Contact Phone: •••-•••-••••
Contact
-
Peking University Third Hospital
NOT_YET_RECRUITINGBeijing, 100191, China
Contact Phone: •••-•••-••••
Contact
-
Renji Hospital, Shanghai Jiaotong University School of Medicine
NOT_YET_RECRUITINGShanghai, 200127, China
Contact Phone: •••-•••-••••
Contact
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, 430022, China
Contact Phone: •••-•••-••••
Contact
-
Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, 410008, China
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.